Accuracy of freestyle libre in adults with type 1 diabetes: the effect of sensor age
Tsoukas M, Rutkowski J, El-Fathi A, et al.
Diabetes Technol Ther. 2020;22(3):203-7
Leggi
Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
Bayona Cebada A, Nattero-Chávez L, et al.
Diabetes Technol Ther. 2020;22(3):208-15
Leggi
Demonstrated cost-effectiveness of a telehomecare program for gestational diabetes mellitus management
Lemelin A, Paré G, Bernard S, Godbout A
Diabetes Technol Ther. 2020;22(3):195-202
Leggi
Safety and performance of the omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions
Sherr JL, Buckingham BA, Forlenza GP, et al.
Diabetes Technol Ther. 2020;22(3):174-84
Leggi
Fifteen-year trends of cardiogenic shock and mortality in patients with diabetes and acute coronary syndromes
Dauriz M, Morici N, Gonzini L et al.
Am J Med. 2020;133(3):331-339.e2
Leggi
Does metformin interfere with the cardiovascular benefits of SGLT2 inhibitors? Questions about its role as the cornerstone of diabetes treatment
Packer M
American Journal of Medicine. Pub online 12 February 2020
Leggi
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Z, Xiaoxia Y, Zheng Y, et al.
Lancet Diabetes Endocrinol. 2020;8(3):192-205
Leggi
Impact of hyperglycemia on long-term outcome in patients with st-segment elevation myocardial infarction
Kojima T , Hikoso S , Nakatani D, et al.
Am J Cardiol. 2020;125(6):851-9
Leggi
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Maddaloni E, Coleman RL, Agbaje O, et al.
Lancet Diabetes Endocrinol. 2020;8(3):206-15
Leggi